Future studies should examine XZF in acquired resistance models to PD-1/PD-L1 inhibitors, investigate its effects on other immune checkpoints, assess long-term T-cell function impacts, and evaluate its influence on resistant tumor microenvironments. The gene discussed is PDCD1; the disease is neoplasm.